Back to News
Market Impact: 0.35
Ligand Reports Third Quarter 2026 Financial Results
Source: Nasdaq
Corporate EarningsCompany Fundamentals
Ligand Pharmaceuticals reported third-quarter 2026 total revenues and income of $78.7 million, down 32% from $115.5 million in the prior-year period. The provided article text does not include further results or outlook details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.35
Ticker Sentiment
LGND-0.55
More News
- DoorDash offers $17 billion for Instacart: ‘the largest companies are only eating more and more of the pie’
- Alphabet Erases $500 Billion as ChatGPT, Google AI Cut into Search
- Alphabet just had its worst day as a public company. BofA now values Google search at a lower multiple than fossil fuel stocks
- Norwegian shares surge 13% on earnings beat, guidance raise
- Taiwan Stocks Heads for Correction as Global AI Selloff Deepens
- Asia stocks tumble as AI spending concerns deepen; BOJ holds rates